- 1 Evaluate the risk in conventional IVF frozen human blastocysts undergoing PGT using a
- 2 new quantification method for parental contamination testing (qPCT)
- 3 Authords: Yunqiao Dong, Ph.D.,^a Dun Liu, Ph.D.,^a Yangyun Zou Ph.D.,^b Cheng Wan Ph.D.,^b
- 4 Chuangqi Chen, M.S.,^a Mei Dong M.D.,^a Ph.D.,^a Yuqiang Huang M.S.,^a Cuiyu Huang M.S.,^a
- 5 Huinan Weng M.D.,^a Ph.D.,^a Xiulan Zhu M.D.,^a Ph.D.,^a, Fang Wang M.D.,^a Ph.D.,^a Shujing Jiao
- 6 M.S.,^b Na Liu M.S.,^b Sijia Lu Ph.D.,^b Xiqian Zhang, M.D.,^a Ph.D.,^a Fenghua Liu, M.D.^a
- 7 Affiliations:
- ^a Reproductive Medical Center, Guangdong Women and Children Hospital, Guangzhou Medical
- 9 University, Guangzhou, 511400, Guangdong Province, China; ^b Yikon Genomics Company, Ltd.,
- 10 Shanghai 201499, China
- 11 Y.D., D.L., Y.Z. and C.W. should be considered similar in author order.
- 12 Corresponding Author: Fenghua Liu,
- 13 No.521 Xingnan Rd., Guangzhou 511400, Guangdong Province, China.
- 14 Tel:86-20-39151861
- 15 E-mail: liushine2006@163.com
- 16 Capsule:
- 17 During PGT for human frozen conventional IVF embryos, paternal source pollution is negligible,
- 18 while maternal pollution can not be ignored. qPCT method can effectively detect the parent DNA
- 19 contamination in WGA products of biopsied TE cells.
- 20

- 21 Abstract:
- 22 **Objective:** To establish a method to assess risks associated with preimplantation genetic testing
- 23 (PGT) in embryos simultaneously with adhered sperm and cumulus cells.
- 24 **Design:** A prospective pilot study.
- 25 **Setting:** University teaching hospital.
- 26 Patient(s): 120 frozen blastocysts that could be biopsied from 34 patients who had experienced
- 27 repeated implantation failure or abortion due to chromosomal abnormalities after embryos transfer
- 28 in prior routine IVF cycles.
- 29 Intervention(s): Chromosome screening and parental DNA contamination testing was performed
- 30 in the surplus frozen IVF blastocysts from 34 patients.

31 Main Outcome Measure(s): Parental DNA contamination rate and euploidy rate in biopsied

32 blastocysts.

33 Result(s): A new quantification method for parental contamination testing (qPCT) in single-cell 34 whole-genome amplification (WGA) products based on allelic ratio analysis was established and 35 validated in an artificial model by comparing 22 results obtained before and after adding different 36 numbers of sperm and cumulus cells to biopsied TE cells. The results of the prospective clinical 37 study of qPCT-PGT-A showed that the maternal contamination rate was 0.83% (1/120) and the 38 risk of paternal contamination was negligible. The euploidy rate in these blastocysts was 47.50% 39 (57/120), and 21 frozen embryo transfer (FET) cycles resulted in ten ongoing clinical pregnancies 40 and four healthy births.

41 Conclusion(s): The evidence we provide in the study shows a low risk of PGT in embryos 42 simultaneously with adhered sperm and cumulus cells. The qPCT assay can be used to detect the 43 risk of potential contamination and ensure the accuracy of PGT results, thereby improving the 44 clinical outcome of IVF.

45 Key Words: Quantitative parental contamination testing, IVF, PGT, biopsy, human blastocyst46

47 Introduction

48 For preimplantation genetic testing (PGT) to be clinically applicable, intracytoplasmic sperm 49 injection (ICSI) is usually required, rather than conventional in vitro fertilization (IVF) 50 insemination method, owing to potential parental contamination from sperm and cumulus cells 51 attached to the zona pellucida during conventional IVF (1-6). However, in many available studies 52 addressing non-male factor infertility, ICSI has not been proven to be beneficial for clinical outcomes, and the risk of chromosomal defects is increased in ICSI offspring (7-12). Since sperm 53 54 DNA fails to amplify under the conditions used for trophectoderm (TE) biopsy samples, and 55 cumulus cells will be deliberately removed clearly in fresh IVF-PGT-A, the use of conventional 56 IVF has been preliminarily explored in fresh genetic testing for aneuploidies (PGT-A) cycles in 57 recent years (13-15). However, if without an intention to perform PGT in the beginning, there are 58 many sperm and cumulus cells exist simultaneously in the zona pellucida of conventional IVF 59 frozen blastocysts. Little is known about the maternal contamination risk of PGT in these embryos 60 and whether it adversely affects the accuracy of results in conventional IVF-PGT. Recently, a 61 study shows that 12.5% maternal DNA contamination was observed in blastocyst media, 62 indicating that potential maternal contamination should not be neglected (16).

63 Currently, the clinical need for PGT-A in frozen conventional IVF embryos is urgent. For 64 patients who have experienced repeated implantation failure or abortion due to chromosomal 65 abnormalities in previous embryo transfer cycles, the biopsy of the existing frozen embryos is not 66 only necessary but also cost-effective. However, there are many cumulus cells and sperm in the 67 zona pellucida especially from conventional IVF embryos, especially when there is no PGT 68 expectation in advance. With current methods, parental contamination in biopsy cells cannot be 69 detected accurately. Therefore, we verified whether PGT-A is feasible for embryos with potential 70 parental contamination.

To address this issue, we developed a parental contamination detection method for biopsy cells which could exclude contaminated embryos and ensure the accuracy of PGT results. Thus far, several approaches using single nucleotide polymorphism (SNP) genotyping information or short tandem repeat (STR) markers to trace maternal genetic materials from fetal or miscarriage specimens have been reported (17-19). However, such approaches require sufficient DNA for genetic testing. Esteki and his collaborators proposed a concurrent whole-genome haplotyping

approach referred to as haplarithmisis to resolve the parental origin of copy number variations
(CNVs) in single cells, but the method is easily affected by low-quality amplification effects, such
as high allele dropout (ADO) (20). To the best of our knowledge, no previous studies have
reported parental contamination detection in single-cell whole-genome amplification (WGA)
products from TE biopsied cells.

82 In this study, we first developed a new quantification method for parental contamination 83 testing (referred to as qPCT) based on allelic ratios obtained from SNP genotypes that fully 84 considers amplification bias, including preferential amplification or ADO effects. The qPCT assay 85 was validated by comparing results before and after the artificial addition of sperm and cumulus 86 cells to TE cells from discarded aneuploidy blastocysts. We then recruited 120 frozen embryos 87 from 34 couples, with advanced age, experienced repeated implantation failure or abortion due to 88 chromosome abnormalities, who had surplus frozen embryos from previous conventional IVF 89 cycles available for biopsy. By using next-generation sequencing (NGS) with our qPCT method, 90 we selected euploidy embryos with no parental contamination for transfer, resulting in four 91 healthy live birth and ten ongoing clinical pregnancies. The method has the potential for 92 application in much wider chromosome screening in clinical IVF due to increasing clinical needs 93 and the limitations of the existing methods.

94

95 Materials and Methods

96 **Preparation of embryos for the study.** To establish the qPCT method, 30 reference samples, 97 which are WGA products with normal PGT-A results and no parental contamination were 98 collected, and to perform the simulated contamination test, six discarded aneuploidy embryos 99 were collected. We conducted a prospective clinical study with patients recruited from January 100 2020 to April 2021. A total of 34 couples with indications for PGT-A due to advanced maternal 101 age, repeated implantation failures or recurrent abortion who had surplus blastocysts from prior 102 conventional IVF available for biopsy were recruited regardless of their prognosis, age, or 103 diagnosis. The couples had no karyotype abnormalities. Approval for this study was obtained from 104 the Ethics Committee of Guangdong Women and Children Hospital (Research Ethics Committee 105 No. 202101109). All these samples were from Reproductive Medical Center of Guangdong 106 Women and Children Hospital and all of the patients signed the informed consent form before any

107 study-specific procedures were performed. The whole protocol described below is summarized in

108 Figure. 3A. The clinical details of 34 couples are summarized in Table 2.

Artificial addition of sperm and cumulus cells to TE cells. To establish an artificial model for detecting parental cells contamination in biopsied TE cells, frozen-thawed sperm and cumulus cell was isolated, aspirated and put into the pipette with biopsy cells. To simulate the freezing process of sperm on the zona pellucida, the method involving the zona pellucida combined with sperm was used (Supplementary, Figure. S1).

114 Blastocyst biopsy. Frozen stage 5 or 6 blastocysts were thawed in advance and cultured 2-4 h 115 prior to biopsy, whereas frozen day 3 embryos were thawed 2–3 days in advance. Every blastocyst 116 that reached the blastocyst stage and fulfilled the biopsy criteria was biopsied. Biopsy was 117 performed in 10-µl drops of G-MOPS-PLUS, the blastocyst was fixed and positioned with a clear 118 view of the inner cell mass (ICM) at 9-12 o'clock, and the hatched TE cells were aspirated into the biopsy pipette, followed by three laser pulses of 2.0 ms (ZYLOS-tk[®], Hamilton Thorne, MA, USA) 119 120 to loosen cell connections and the application of the mechanical 'flicking' method to cut away the 121 TE cells using the biopsy pipette and holding pipette. When a blastocyst was not hatched, the zona 122 pellucida was perforated by a laser for 2.0 ms, after which the collapse of the blastocyst was 123 induced before biopsy. TE cells were washed and placed in 0.2-ml PCR tubes with 1-2.0 µl PBS 124 and stored at -20° C until further processing. Approximately 10 biopsy cells from one discarded 125 aneuploidy blastocyst were artificially mixed with sperm or cumulus cells and 4-6 TE cells were 126 biopsied for clinical application of qPCT-PGT. All embryos were cryopreserved by vitrification 127 (Life Global[®], USA) within 1 h after biopsy and stored at -196°C.

128 Whole-genome amplification of sperm, cumulus and TE cells. Single-cell WGA were 129 performed in 22 samples of sperm cells (20 cells per sample) and three samples of cumulus cells 130 (one cell per sample) under different conditions used for TE biopsy samples (Figure. 1A and 1B). 131 The multiple annealing and loop-based amplification cycles (MALBAC)-based single-cell WGA 132 kit (ChromSwiftTM, Cat. No. KT110700324, Yikon Genomics Ltd, Suzhou, China), the 133 PicoPLEX single-cell WGA kit (Rubicon Genomics, Ann Arbor, USA) and the multiple 134 displacement amplification (MDA)-based single-cell WGA Kit (Cat. No. 150343, Qiagen, USA) 135 were utilized to amplify DNA from different types of cells according to the manufacturer's 136 instructions.

Determination of blastocyst ploidy status by NGS. To analyze the ploidy status of blastocysts, the amplified DNA of TE samples was sequenced using a NextSeq 550 sequencer (Cat No. SY-415-1002, Illumina, Inc., USA) with a single-ended read length of 55 bp. Approximately 2 million raw reads were generated for each TE sample. Genome-wide CNVs were analyzed to determine the euploidy or aneuploidy status of each embryo. Aneuploid embryos were diagnosed when the size of CNVs was greater than 4 Mb and the extent of mosaicism was above 30%.

143 Genotyping assay of blastocysts and parental genomes. To determine the genotype of each 144 blastocyst and parental genome, the Infinium Asian Screening Array (ASA) bead chip (Cat No. 145 20016317, Illumina, Inc., USA) and the iScan system (Cat No. SY-101-1001, Illumina, Inc., USA) 146 were utilized. Parental genomic DNA was extracted from the peripheral blood of the parents of 147 each blastocyst. Genomic DNA, along with the amplified DNA of TE samples, was linearly 148 amplified, fragmented, precipitated and hybridized according to the manufacturer's instructions. 149 Signal scanning was performed with the iScan system. Iaap-cli gencall algorithm (Version 1.1.0, 150 Illumina, Inc., USA) was applied to analyze the genotype of each sample, and the BAF and log R 151 ratio (LRR) values of all SNPs were generated simultaneously.

152 Determination of parental contamination by BAF analysis. As shown in (Figure. 1F), 153 theoretically, the BAFs of genotypes AA, AB and BB should be approximately 0, 0.5 and 1, 154 respectively. For a SNP with paternal AA and maternal BB genotypes or paternal BB and 155 maternal AA genotypes, the genotype of the embryo is genetically expected to be heterozygous 156 AB, with a BAF of approximately 0.5. Deviation from a BAF of 0.5 for the embryo may be 157 caused by parental contamination, DNA copy number aberrations or allelic amplification bias and 158 errors (e.g. allele dropout or preferential amplification of one allele) resulting from single-cell 159 WGA technology. Selecting SNP j with homozygous genotypes but different alleles between the 160 father and mother, maternally and paternally biased SNPs in an embryo were defined according to 161 a BAF ≥ 0.6 (S_M, SNP site for maternal bias) and BAF ≤ 0.4 (S_P, SNP site for paternal bias) given 162 maternal and paternal genotypes of BB and AA, respectively; for maternal and paternal genotypes 163 of AA and BB, maternally and paternally biased SNPs were determined according to a BAF ≤ 0.4 164 (S_M) and BAF ≥ 0.6 (S_P) (Figure. 1F). Relative parental origin bias (POB) statistics were thus 165 constructed and formulated for each chromosome, i, as follows:

166
$$R_{POB_i} = \frac{\sum_j S_{M_{i,j}}}{\sum_j S_{P_{i,j}}}$$

167

168 Based on reference samples from euploid embryos without parental contamination, a positively 169 skewed normal distribution of R_{POB} , with a mean value of 1.14 was obtained (Figure. S1B). Here, a tested sample with an R_{POB_i} value significantly greater than 1.14 is indicated to show 170 171 maternal origin bias, implying maternal contamination (most chromosomes with numbers ≥15 172 share the same pattern), or chromosome-level maternal-origin DNA replication, or uniparental 173 disomy, or paternal-origin DNA deletion with a *P*-value < 0.05 (Mean+3*SD); on the contrary, a tested sample with an R_{POB_i} value significantly less than 1.14 is indicated to show 174 175 paternal-origin bias, with the possibility of paternal contamination (most chromosomes with 176 numbers \geq 15 share the same pattern), or chromosome-level paternal-origin DNA replication, or 177 uniparental disomy, or maternal-origin DNA deletion with a P-value <0.05 (Mean-2*SD, standard 178 deviation). R_{POB} statistics can to some degree eliminate allelic amplification bias from WGA.

179 Preparation and analyzing of artificially contaminated gDNA. To address the issue of 180 quantification of parental contamination, we establish a standard curve, which represents the 181 correlation between the POB value and the ratio of parental contamination. Parents genomic DNA 182 was extracted from peripheral blood samples, while fetal genomic DNA was extracted from tissue 183 of spontaneous abortion. A commercial genomic DNA extraction kit (DNeasy Blood & Tissue Kit, 184 Cat. No. 69504, Qiagen, USA) was used according to the manufacturer's instructions. Paternal/fet 185 al and maternal/fet al DNA was mixed in different proportion (Figure. 1G). The artificially 186 contaminated DNA was then diluted to 50pg/µL, and amplified by using a ChromInst Single cell 187 WGA kit (Cat. No. Yikon Genomics Ltd, Suzhou, China) according to the manufacturer's 188 instructions. Finally, the amplified DNA was analyzed by using the Infinium Asian Screening 189 Array (ASA) bead chip (Cat No. 20016317. Illumina, Inc. USA) and the iScan system (Cat No. 190 SY-101-1001. Illumina, Inc. USA) to obtain the BAF value of each SNP loci. The R_{POB} was 191 calculated to establish the standard curve of the ratio of parental contamination.

192 Measurement of clinical outcomes. Biochemical was defined as β -HCG > 5 U/L detected 12

days after blastocyst transfer, but no gestational sac was found by transvaginal ultrasound.
Negative was defined as β-HCG <5 U/L detected 12 days after blastocyst transfer. Clinical
pregnancy was defined by fetal cardiac activity. Non-invasive prenatal testing (NIPT) was
performed at 12–18 weeks of gestation.

- 197
- 198 **Results**

199 WGA of sperm and cumulus cells. We performed WGA and copy number variation sequencing 200 (CNV-seq) in 22 samples of frozen-thawed sperm cells and three samples of frozen-thawed 201 cumulus cells (Figure 1A and 1B). As shown in Figure. 1C, no DNA smears were observed in the 202 MALBAC-WGA and Picoplex-WGA products of the sperm samples, while positive results were 203 obtained from the MDA-WGA products. However, cumulus cell DNA can be easily amplified by 204 the three methods (Figure 1D). The MALBAC-CNV-seq and Picoplex-CNV-seq of sperm 205 samples also failed to generate qualified results, showing low genome coverage of 0.31% to 206 1.08% and relatively high coefficients of variation (CV) ranging from 23% to 50% (Figure 1E). 207 However, three cumulus cell samples presented high-quality CNV-seq results, showing normal 208 karyotypes of the three samples (Figure 1D and 1E). These results are partially in accordance with 209 previous studies (15), indicating the difficulty of amplifying sperm DNA.

210 **Establishment of qPCT.** To establish the qPCT method, we first collected 30 reference samples 211 from euploid embryos without parental contamination, which were defined as embryos with 212 normal ploidy and XY chromosomes. The POB values of these reference samples were calculated 213 based on the B allele frequency (BAF) of selected SNP loci (Figure. 1F and Supplementary Figure. 214 S2) approximately followed a positively skewed normal distribution, with a mean (Mean) of 1.14 215 and standard deviation (SD) of 0.30. Therefore, the POB range for non-contaminating euploid 216 embryos was defined as 0.54 to 2.04 (Mean -2*SD to Mean + 3*SD), and a qualitative standard of 217 parental contamination was established.

To further address the issue of the quantification of parental contamination, gDNA of tissue samples from spontaneous abortions and blood samples from parents was mixed in specific proportions. The mixed gDNA was diluted to an approximate concentration of 50 pg/ μ L and then amplified, sequenced and analyzed in accordance with the PGT-A procedure. Genotyping assays were also performed. As a result, the POB values of the artificially added contaminant fet al

gDNA showed a positive correlation with the proportion of mixed parental gDNA (Figure 1G and
1H). The relative quantification of parental contamination could be performed by using the
standard curve.

226 Detection of contamination in artificially contaminated TE samples. To verify the accuracy 227 and repeatability of qPCT in detecting parental contamination in biopsy cells, we added gDNA 228 from the peripheral blood of parents to the WGA products and found that the detection rate was 229 100% (10/10) (Supplementary Figure S3). However, no significant contamination was detected in 230 artificially contaminated TE samples containing approximately 10 biopsy cells and 1 cumulus cell 231 (Table 1).

To reveal the correlation between the PGT-A results and parental contamination, we selected discarded aneuploid blastocysts, added different numbers of sperm cells or cumulus cells to biopsied TE samples, and performed PGT-A and qPCT in these samples. The results showed that no paternal contamination was detected, and no change in the PGT-A results was observed, regardless of the number of added sperm cells (Figure 2A and Table 1). On the other hand, the proportion of maternal contamination increased gradually with the increase in the number of added cumulus cells, and a notable correlation was observed (Figure 2B and Table 1).

239 Prospective clinical study of qPCT-PGT-A in thawed IVF blastocysts. After the systematic 240 validation of the qPCT assay, we performed qPCT-PGT-A in a total of 120 frozen blastocysts from 241 34 recruited patients as described in the materials. The procedure of qPCT-combined PGT-A is 242 shown in (Figure. 3A) The qPCT results revealed a maternal contamination rate of 0.83% (1/120, 243 case qpcts8), and no paternal contamination was detected, as expected (Table 2 and Figure 3B). 244 Notably, one sample from case qpcts26 was defined as an euploid with suspicious paternal 245 contamination (Table 2 and Supplementary Figure S4A). To confirm this, the sample was 246 collected and lysed for heteroploid detection using the whole embryo, and a paternal origin of 247 triploid result was revealed (Table 2 and Supplementary, Figure S4B). The PGT-A results showed 248 that the euploidy rate of these frozen blastocysts was 47.50% (57/120), and at least one euploid 249 blastocyst was obtained for frozen embryo transfer (FET) in 28 of these patients (Table 2). 250 Single-blastocyst transfer was performed in ternty-one patients, resulting in four healthy birth and 251 ten ongoing clinical pregnancies (Table 2). To date, no early abortion has occurred, and we 252 continue to follow up the last ongoing pregnancy. The detailed clinical indications and outcomes

are summarized in Table 2.

254

255 **Discussion**

256 WGA of sperm cells and the effect on PGT-A. Sperm are the main source of paternal 257 contamination, and sperm attached to the zona pellucida cannot be removed in fresh or frozen 258 embryos from conventional IVF cycles. Several studies have shown that sperm DNA is difficult to 259 be amplified by using routine protocols for TE biopsy samples (15, 21), but little evidence 260 indicating the risk and ratio of paternal contamination in conventional IVF PGT-A has been 261 reported. In this study, a comprehensive investigation of paternal contamination was performed 262 with a 3-step study design. First, we performed MALBAC-WGA of isolated sperm cells, and the 263 results of both agarose gel electrophoresis and CNV-seq showed amplification failure, even if 20 264 sperm cells were tubed (Figure 1C). Although the immobilized motile sperm were subjected to 265 freeze-thawing, the sperm remained intact and did not show signs of degeneration. Also, a similar 266 negative result was found by Neelke et al using PicoPlex WGA (15). In contrast, sperm DNA 267 could be amplified by using MDA (Figure 1C and 1E), indicating a higher risk of paternal 268 contamination in the application of MDA-based PGT in IVF embryos. Second, we performed 269 PGT-A and qPCT with artificially mixed TE and sperm cells, resulting in no change in the PGT-A 270 results and no paternal contamination. Finally, we conducted a prospective clinical study with 120 271 frozen conventional IVF blastocysts; unsurprisingly, no paternal contamination was detected 272 (Table 2). This evidence indicates that the risk of paternal contamination is negligible and that 273 PGT can be applied in patients undergoing conventional IVF with the MALBAC system. As 274 mentioned above, it is difficult to eliminate the possibility that sperm cells could spontaneously 275 disruption in the real world or use other WGA systems.

Maternal contamination from cumulus cells and the effect on PGT-A. Cumulus cells are the main source of maternal genetic contamination in TE samples. Unlike sperm, cumulus cell DNA can be easily amplified during the PGT procedure. A notable correlation between the number of cumulus cells and the proportion of maternal contamination was observed by using the qPCT method (Table 1). The results suggested that severe maternal contamination would lead to false-negative results, and partial maternal contamination would cause to mosaicism Therefore, to identify false-negative results caused by maternal contamination, it is necessary to apply

283 contamination quantification methods, such as qPCT, in the PGT-A of both ICSI and conventional

284 IVF embryos.

285 Advantages and limitations of the qPCT method. In the PGT scenario, biopsy specimens from 286 blastocysts usually require single-cell whole genome amplification to provide sufficient DNA for 287 genetic testing. However, ADO (PCR failure for one allele) and/or preferential amplification 288 (hypoamplification of one allele) resulting from WGA technology cause SNP genotyping to be 289 unreliable (20). Therefore, many proposed parental cell contamination testing methods involving 290 gDNA samples from tissue without WGA cannot be employed in PGT applications (17-19). For 291 this reason, we developed a parental orientation test based on the allelic ratio determined via B 292 allele frequency (BAF) analysis to address the parental contamination issue in IVF-PGT-A. Our 293 method fully considers amplification biases, such as preferential amplification or ADO, which are 294 relatively insensitive to single-cell WGA quality. Meanwhile, combined with WGA specific BAF 295 pattern resolution, parental contamination or heteroploidy may be further discriminative 296 (Supplementary Figure S4). Technically, any WGA method is applicable for qPCT. Also, 297 preimplantation genetic testing for monogenic (PGT-M) as well as preimplantation genetic testing 298 for chromosomal structural rearrangements (PGT-SR) are theoretically feasible for conventional 299 IVF insemination method by using qPCT. The method does not require specialized equipment or 300 complex experimental procedures; therefore, it can be fully adapted for routine use in a molecular 301 diagnostic laboratory. However, this approach requires parental genetic information for combined 302 analysis, thus limiting its large-scale clinical application to some degree. Moreover, a method of 303 parental contamination removal is urgently needed to provide accurate PGT results for biopsy 304 samples, even samples contaminated by parental genetic material. Epigenetic signal discrimination 305 between embryonic and parental cell DNA may be a promising way to trace the cellular origin of 306 DNA samples, which might filter out the effect of parental contamination in the future (22).

307 The need for qPCT clinical application in frozen blastocysts. The biopsy of the existing frozen 308 IVF blastocysts to meet patients' clinical needs not only increases embryo utilization but also 309 reduces physical and economic burdens. Thus, IVF physicians and embryologists must understand 310 and select the programs available to them. The only barrier to this strategy is that the potential risk 311 of parental DNA contamination cannot be excluded. Unlike ICSI-PGT-A or fresh IVF-PGT-A

312 (17-19), cumulus cells are not required to completely removed in conventional IVF when there is 313 no PGT expectation in advance (Figure 3C). As a result, it is difficult to always avoid sperm 314 and/or cumulus cells attached to the spherical zona pellucida during TE cells biopsy (Figure 3D). 315 Moreover, the DNA of sperm or granular cells disrupted by a laser might disperse into the biopsy 316 fluid during biopsy. Therefore, it is necessary to detect parental contamination in biopsy cells 317 under such conditions. Frozen IVF blastocyst biopsy samples will be resuscitated in advance, so 318 the blastocyst TE cells will hatch from the holes generated by freezing and draining water or 319 artificial openings made after thawing. In this study, 71.67% of blastocysts were stage 5 and 6 320 blastocysts with TE cells located far away from the zona pellucida (Supplementary Table 1), 321 which could partly explain the reason for the low contamination detection rate in this study. 322 Admittedly, the major disadvantages of the applied clinical strategy are that (\Box) it requires 323 invasive embryo biopsy and (\Box) repeated cryopreservation of embryos is usually unavoidable. 324 There are still safety concerns with these procedures (23-28). In the future, rapid noninvasive 325 chromosome screening or mutation identification combined with qPCT will be a promising 326 research area (29-33). However, as the clinical strategy yielded a clinical pregnancy rate of 327 57.14% without adverse outcomes, patients with existing frozen conventional IVF embryos could 328 be counseled regarding this new option.

329 In summary, the risk of PGT in embryos with potential parental contamination is relatively low. 330 We have established a practical and easy-to-implement clinical strategy, qPCT, for detecting 331 potential parental contamination from sperm and cumulus cells especially in frozen conventional 332 IVF embryos and ensuring the accuracy of PGT results. Our validation data and initial clinical 333 applications strongly suggest that the qPCT-PGT assay can help to improve clinical outcomes via 334 the chromosome screening of frozen conventional IVF embryos in a manner allowing their reuse. 335 We envision that multicenter randomized clinical trials will be designed and performed in the 336 future, which will further evaluate the clinical safety and effectiveness of the qPCT-PGT assay.

337

338

339 Acknowledgements

- 340 We thank the patients for their participation in this study. This work was supported by grants from
- the Science and Technology Program of Guangzhou (201704020217), the National Key Research
- 342 and Development Program of China (2018YFC1002604) and the National Natural Science
- 343 Foundation of China (81800184).
- 344

345 Author Contributions:

- 346 Y.D., D.L., C.W., Y.Z., S.L., X.Z., F.L. designed research; Y.D., D.L., C.C., M.D., Y.H., C.H.,
- 347 H.W., X.Z., F.W., X.Z., N.L. performed research; Y.D., D.L., C.W., Y.Z., S.J., S.L., F.L. analyzed
- 348 data; Y.D., D.L., C.W., Y.Z. wrote the paper.

349

350

351

352

353 **References**

- 1.Thornhill AR, deDie-Smulders CE, Geraedts JP, Harper JC, Harton GL, Lavery SA, etal.
 ESHRE PGD Consortium. ESHRE PGD Consortium 'Best practice guidelines for clinical
 preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)'. Hum
 Reprod 2005;20:35-48.
- 2. ESHRE Capri Workshop Group. Intracytoplasmic sperm injection (ICSI) in 2006: evidence and
 evolution. Hum Reprod Update 2007;13:515-526.
- 360 3.Harton GL, Magli MC, Lundin K, Montag M, Lemmen J, Harper JC; European Society for
- 361 Human Reproduction and Embryology (ESHRE) PGD Consortium/Embryology Special Interest
- 362 Group. ESHRE PGD Consortium/Embryology Special Interest Group--best practice guidelines for
- 363 polar body and embryo biopsy for preimplantation genetic diagnosis/screening (PGD/PGS). Hum
- **364** Reprod 2011;26:41-46.
- 4.Berger VK, Baker VL. Preimplantation diagnosis for single gene disorders. Semin Reprod Med
 2014;32:107-113.
- 367 5.Kokkali G, Coticchio G, Bronet F, Celebi C, Cimadomo D, Goossens V, etal. ESHRE PGT
 368 Consortium and SIG Embryology good practice recommendations for polar body and embryo

biopsy for PGT. Hum Reprod Open 2020;2020:hoaa020.

- 370 6.Coonen E, Rubio C, Christopikou D, Dimitriadou E, Gontar J, Goossens V, etal. ESHRE PGT
- 371 Consortium good practice recommendations for the detection of structural and numerical
- 372 chromosomal aberrations. Hum Reprod Open 2020;2020:hoaa017.
- 373 7.Ming L, Yuan C, Ping Z, Ping L, Jie Q. Conventional in vitro fertilization maybe yields more
- available embryos than intracytoplasmic sperm injection for patients with no indications for ICSI.
- 375 Int J Clin Exp Med 2015;8:21593-21598.
- 376 8.Grimstad FW, Nangia AK, Luke B, Stern JE, Mak W. Use of ICSI in IVF cycles in women with
- tubal ligation does not improve pregnancy or live birth rates. Hum Reprod 2016;31:2750-2755.
- 378 9.Tannus S, Son WY, Gilman A, Younes G, Shavit T, Dahan MH. The role of intracytoplasmic
- 379 sperm injection in non-male factor infertility in advanced maternal age. Hum Reprod380 2017;32:119-124.
- 381 10.Sustar K, Rozen G, Agresta F, Polyakov A. Use of intracytoplasmic sperm injection (ICSI) in
- 382 normospermic men may result in lower clinical pregnancy and live birth rates. Aust N Z J Obstet

383 Gynaecol 2019;59:706-711.

- 384 11.Farhi J, Cohen K, Mizrachi Y, Weissman A, Raziel A, Orvieto R. Should ICSI be implemented
- 385 during IVF to all advanced-age patients with non-male factor subfertility? Reprod Biol Endocrinol386 2019;17:30.
- 387 12.Luke B, Brown MB, Wantman E, Forestieri NE, Browne ML, Fisher SC, Yazdy MM, Ethen
- 388 MK, Canfield MA, Watkins S, et al. The risk of birth defects with conception by ART. Hum389 Reprod 2021;36:116-129.
- 390 13.Feldman B, Aizer A, Brengauz M, Dotan K, Levron J, Schiff E, etal. Pre-implantation genetic
- diagnosis-should we use ICSI for all? J Assist Reprod Genet 2017;34:1179-1183.
- 392 14.Niu X, Long J, Gong F, Wang W. Does ICSI for in vitro fertilization cause more aneuploid
- embryos? Mol Cytogenet 2020;13:27.
- 394 15.Neelke De Munck N, El Khatib I, Abdala A, El-Damen A, Bayram A, Arnanz A, etal.
- Intracytoplasmic sperm injection is not superior to conventional IVF in couples with non-malefactor infertility and preimplantation genetic testing for aneuploidies (PGT-A). Hum Reprod
- **397** 2020;35:317-327.
- 398 16.Rubio C, Navarro-Sánchez L, García-Pascual CM, Ocali O, Cimadomo D, Venier W, etal.
 399 Multicenter prospective study of concordance between embryonic cell-free DNA and
 400 trophectoderm biopsies from 1301 human blastocysts. Am J Obstet Gynecol 2020;223:751.
- 401 17.Liao GJ, Chan KC, Jiang P, Sun H, Leung TY, Chiu RW, etal. Noninvasive prenatal diagnosis
- 402 of fet al trisomy 21 by allelic ratio analysis using targeted massively parallel sequencing of403 maternal plasma DNA. PLoS One 2012;7:e38154.
- 404 18.Lathi RB, Gustin SL, Keller J, Maisenbacher MK, Sigurjonsson S, Tao R, etal. Reliability of
- 405 46,XX results on miscarriage specimens: a review of 1,222 first-trimester miscarriage specimens.
- 406 Fertil Steril 2014;101:178-182.
- 407 19.Buchovecky CM, Nahum O, Levy B. Assessment of Maternal Cell Contamination in Prenatal
- 408 Samples by Quantitative Fluorescent PCR (QF-PCR). Methods Mol Biol 2019;1885:117-127.
- 409 20.Zamani Esteki M, Dimitriadou E, Mateiu L, Melotte C, Van der Aa N, Kumar P, etal.
- 410 Concurrent whole-genome haplotyping and copy-number profiling of single cells. Am J Hum
- 411 Genet 2015;96:894-912.
- 412 21.Patassini C, Garolla A, Bottacin A, Menegazzo M, Speltra E, Foresta C, etal. Molecular

- 413 karyotyping of human single sperm by array- comparative genomic hybridization. PLoS One
- 414 2013;8:e60922.
- 415 22 Chen Y, Gao Y, Jia J, Chang L, Liu P, Qiao J, etal. DNA methylome reveals cellular origin of
- 416 cell-free DNA in spent medium of human preimplantation embryos. J Clin Invest
- 417 2021;131:e146051.
- 418 23.Koch J, Costello MF, Chapman MG, Kilani S, Twice-frozen embryos are no detriment to
 419 pregnancy success: a retrospective comparative study. Fertil Steril 2011;96:58-62.
- 420 24.Zhao HC, Zhao Y, Li M, Yan J, Li L, Li R, etal. Aberrant epigenetic modification in murine
- 421 brain tissues of offspring from preimplantation genetic diagnosis blastomere biopsies. Biol Reprod422 2013;89:117.
- 423 25.Zeng Y, Lv Z, Gu L, Wang L, Zhou Z, Zhu H, etal. Preimplantation genetic diagnosis (PGD)
- 424 influences adrenal development and response to cold stress in resulting mice. Cell Tissue Res425 2013;354:729-741.
- 426 26. Wu Y, Lv Z, Yang Y, Dong G, Yu Y, Cui Y, etal. Blastomere biopsy influences epigenetic
- reprogramming during early embryo development, which impacts neural development and
 function in resulting mice. Cell Mol Life Sci 2014;71:1761-1774.
- 429 27.Cimadomo D, Capalbo A, Ubaldi FM, Scarica C, Palagiano A, Canipari R, etal. The Impact of
- 430 Biopsy on Human Embryo Developmental Potential during Preimplantation Genetic Diagnosis.
- 431 Biomed Res Int 2016; 2016:7193075.
- 432 28.Zheng X, Chen Y, Yan J, Wu Y, Zhuang X, Lin S, etal. Effect of repeated cryopreservation on
- 433 human embryo developmental potential. Reprod Biomed Online 2017;35:627-632.
- 434 29. Fang R, Yang W, Zhao X, Xiong F, Guo C, Xiao J, etal. Chromosome screening using culture
- 435 medium of embryos fertilised in vitro: a pilot clinical study. J Transl Med 2019;17:73.
- 436 30.Jiao J, Shi B, Sagnelli M, Yang D, Yao Y, Li W, etal. Minimally invasive preimplantation
 437 genetic testing using blastocyst culture medium. Hum Reprod 2019;34:1369-1379.
- 438 31. Huang L, Bogale B, Tang Y, Lu S, Xie XS, Racowsky C. Noninvasive preimplantation genetic
- 439 testing for an uploidy in spent medium may be more reliable than trophectoderm biopsy. Proc
- 440 Natl Acad Sci U S A. 2019;116:14105-14112
- 441 32. Liu W, Liu J, Du H, Ling J, Sun X, Chen D. Non-invasive pre-implantation aneuploidy
- 442 screening and diagnosis of beta thalassemia IVSII654 mutation using spent embryo culture

- 443 medium. Ann Med 2017 ;49:319-328.
- 444 33. Xu J, Fang R, Chen L, Chen D, Xiao JP, Yang W, etal. Noninvasive chromosome screening of
- 445 human embryos by genome sequencing of embryo culture medium for in vitro fertilization. Proc
- 446 Natl Acad Sci U S A 2016;113:11907-11912
- 447
- 448

449 Figure captions

450	Figure 1. Concept validation and establishment of qPCT. A and B: Isolated sperm and cumulus
451	cells. Bar = 10 μ m. C and D: Electrophoresis for WGA products of sperm and cumulus cells. M:
452	100 bp DNA marker; NC: negative control; C-MAL: 20 sperm cells amplified by MALBAC;
453	C-Pico: 20 sperm cells amplified by Picoplex; C-MDA: 20 sperm cells amplified by MDA.
454	D-MAL: single cumulus cell amplified by MALBAC; D-Pico: single cumulus cell amplified by
455	Picoplex; D-MDA: single cumulus cell amplified by MDA. E: CNV-seq results of WGA products
456	amplified sperm and cumulus cells using MALBAC/Picoplex/MDA. Upper: sperm cells; lower:
457	single cumulus cell; NC: negative control. F: Schematic of assignment of SNP sites for
458	paternal/maternal bias. S_M : SNP site for maternal bias; S_P : SNP site for paternal bias. G: Standard
459	curve of qPCT established by artificially mixed parental and fetal gDNA. X-axis: ratio of added
460	maternal/paternal gDNA; Y-axis: POB value (log10); Red triangle: maternal contamination
461	samples; Blue rhombus: paternal contamination samples. H: qPCT results for artificially
462	contaminated gDNA samples. X-axis: chromosome ID; Y-axis: POB value; M5: 50% maternal
463	contamination sample (maternal DNA : fetal DNA = 1:1); N0: no contamination sample; P5: 50%
464	paternal contamination sample (paternal DNA : fetal DNA = 1:1).
465	Figure 2. Validation of qPCT in the artificial model. A: Sperm cells (3 to 8 cells) were artificially

added to approximately 10 biopsy TE cells respectively. B: Cumulus cells (1 to 3 cells) were
artificially added to approximately 10 biopsy TE cells respectively.

Figure 3. Clinical application of qPCT-combined PGT-A in human conventional IVF embryos. A:
Workflow of qPCT-combined PGT-A. B: Clinical sample with positive results of qPCT. Case ID
qpcts8: maternal contamination. C: Three clinical application scenarios of PGT. Fresh ICSI-PGT:
PGT in fresh blastocysts from ICSI cycles. Fresh IVF-PGT: PGT in fresh blastocysts from
conventional IVF cycles. Frozen IVF-PGT: PGT in frozen-thaw blastocysts from conventional
IVF cycles. D: Typical IVF embryos undergoing TE cells biopsy. Bar = 10µm.

474

475

			No. of			
			added			
			sperm cell			
	Discarded		or		Results of	
Type of artificial	aneuploid		cumulus		parental	Ratio of parental
contamination	embryo	Karyotype	cell	Results of PGT-A	contamination	contamination [*]
Paternal		46,XY,+15(×3),-22(×1)	3	46,XY,+15,-22	NO	0%
Paternal	1	46,XY,+15(×3),-22(×1)	5	46,XY,+15,-22	NO	0%
Paternal	1	46,XY,+15(×3),-22(×1)	8	46,XY,+15,-22	NO	0%
Paternal		46,XY,+15(×3),-22(×1)	20	46,XY,+15,-22	NO	0%
Paternal		45,XY,-20(×1)	3	45,XY,-20	NO	0%
Paternal	h	45,XY,-20(×1)	5	45,XY,-20	NO	0%
Paternal	Z	45,XY,-20(×1)	8	NA [¶]	NA [¶]	NA [¶]
Paternal		45,XY,-20(×1)	20	45,XY,-20	NO	0%
Paternal		47,XX+16(×3)	3	47,XX,+16	NO	0%
Paternal	2	47,XX+16(×3)	5	47,XX+16	NO	0%
Paternal	3	47,XX,+16(×3)	8	47,XX,+16	NO	0%
Paternal		47,XX,+16(×3)	20	47,XX,+16	NO	0%
Maternal		45,XX,-20(×1)	1	45,XX,-20(×1) [§]	NO	0%
Maternal	4	45,XX,-20(×1)	2	46,XX,-20(×1,mos,73%)	YES	20%
Maternal		45,XX-20(×1)	3	46,XX,-20(×1,mos,71%)	YES	32%
Maternal		45,XX-22(×1)	1	45,XX,-22(×1,mos,89%)	NO	0%
Maternal	5	45,XX-22(×1)	2	46,XX,-22(×1,mos,70%)	YES	22%
Maternal		45,XX-22(×1)	3	46,XX,-22(×1,mos,68%)	YES	34%
Maternal	6	45,XY,-22(×1)	8	46,XY,+X(×2,mos,66%),-Y(×0,mos,52%)	YES	59%

476 Table 1 Validation results of the qPCT method in the artificial model.

Maternal	45,XY,-22(×1)	12	46,XY,+X(×2,mos,45%),-Y(×0,mos,45%),-22(×1,mos,41%)	YES	60%
			46,XY,+Xp(p22.33→p22.2,~15Mb,×2),+Xp(p21.1→p11.21		
Maternal	45,XY,-22(×1)	15	,~26Mb,×2),+Xq(×2,mos,70%),-Y(×0,mos,63%)	YES	>70%
			$16 YY \pm Y(x) \mod 63\% = V(x) \mod 62\%$		
Maternal	45,XY,-22(×1)	40	40,~1,+~(^2,1103,0370),-1(^0,1103,0270)	YES	>70%

477 *The cut-off for qPCT is set as 10%.

478 [¶]Failed NGS.

479 [§]Over 10 biopsy TE cells mixed with single cumulus cell or failed addition of the single cumulus cell.

480





Α

В





qPCT analysis: maternal contamintaion



D

Frozen IVF PGT-A

